NASDAQ: TCRX
TScan Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$56.19M
52w High
$2.57
52w Low
$0.85
P/E
-0.96
Volume
283.68K
Outstanding Shares
61.07M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 36.99% over the last year. Revenue grew 106.65% over the trailing twelve months. Operating margin moved from -3,159.87% to -1,408.73%. Free cash flow declined 0.94% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -1,408.73%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
7
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.27 · Revenue est $1.88M
View